作者: Maribel Acosta-Tejeda , Héctor Baptista-González , Fany Rosenfeld-Mann , Rocio Trueba-Gómez , Ethel García-Latorre
DOI: 10.1016/J.THROMRES.2011.05.019
关键词:
摘要: Abstract Introduction The objective was to evaluate if thrombin-activated fibrinolysis inhibitor (TAFI) polymorphisms (G505A, C1040T, and G-438A), TAFIa plasma levels are associated with preeclampsia. Materials Methods In a case-control study design, we evaluated preeclampsia patients women uncomplicated pregnancies. TAFI were determined by real-time PCR method, established chromogenic assay. Results We included 87 in each group. the group 20.4 μg/mL (CI 95% 17.3-23.5), while control group, they significantly lower: 13.3 μg/mL (12.0-14.5, p 0.003). There no differences genotype distribution or allelic frequency of between two groups. controls heterozygous for G505A polymorphism, values 22.8 (16.7-28.9 μg/mL) 13.2 (11.3-15.0 μg/mL, 0.019), respectively. homozygous polymorphism 25.7 (18.7-32.6 μg/mL) 13.5 (1.6-21.9 μg/mL, 0.041), C1040T G-438A wild type polymorphisms, 18.3 (12.5-23.9 μg/mL) 11.5 (9.9-35.0, 0.033), 19.4 (10.9-27.9 μg/mL) 12.5 (10.8-14.2 μg/mL, 0.006), respectively, without other genotypes. Conclusions Preeclampsia itself may be responsible increase rather than presence polymorphisms.